“Recent Publications by Dr. Studin”
Amazon Targeting the transactional in the Pharm Market 10/11/2024
https://www.pharmexec.com/view/amazon-targeting-the-transactional-in-the-pharma-market
Price Elasticity and Inelasticity of Restriction 8/13/2024
https://www.pharmexec.com/view/price-elasticity-and-inelasticity-of-restriction
Latent Benefit of Access Restrictions for Rare Conditions 4/12/2024
https://www.pharmexec.com/view/latent-benefit-of-access-restrictions-for-rare-conditions
Two frameworks for Orphans Drug IDN Launch Planning 2/15/2024
https://www.pharmexec.com/view/two-frameworks-orphan-drug-idn-launch-planning
Obesity Drugs in the Payer Market: What to Expect 10/12/2023
https://www.pharmexec.com/view/obesity-drugs-payer-market-expect
‘Bolus’ Markets: Unique Business Opportunities with Promise and Risk 7/6/2023
https://www.pharmexec.com/view/bolus-markets-unique-business-opportunities-promise-risk
The Payer Value Deficit in Orphan Drugs 4/10/23
https://www.pharmexec.com/view/payer-value-deficit-orphan-drugs
Payer Key Business Factors for Orphan Product Launches 1/11/23
https://www.pharmexec.com/view/payer-key-business-factors-for-orphan-product-launches
Exploring Fixed and Variable Coverage Principles 10/11/22
https://www.pharmexec.com/view/exploring-fixed-and-variable-coverage-principles
If Non-Formulary Hospital, Price May Not Be the Rx 7/8/22
https://www.pharmexec.com/view/if-a-non-formulary-hospital-price-may-not-be-the-rx
The Case for Elevating a Brand’s Price Proposition 4/11/22
https://www.pharmexec.com/view/the-case-for-elevating-a-brand-s-price-proposition
Planning for Second to Market in Orphan Disease Space 2/9/22
https://www.pharmexec.com/view/planning-for-second-to-market-in-orphan-disease-space
Playing the Long Game on Tighter Than Label Coverage 12/9/21
https://www.pharmexec.com/view/playing-the-long-game-on-tighter-than-label-coverage
Could Time Be the Next New Element in Pharma Revenue? 10/21/21
https://www.pharmexec.com/view/could-time-be-the-next-new-element-in-pharma-revenue
Early Payer-Related Lessons for Pharma Post-Aduhelm Approval 8/10/21
https://www.pharmexec.com/view/early-payer-related-lessons-for-pharma-post-aduhelm-approval
Product Analogs Point to Pricing and Distinct Payer Market Scenarios 6/9/21
https://www.pharmexec.com/view/product-analogs-point-to-pricing-and-distinct-payer-market-scenarios
COVID’s Tactical Impact on Health Plan/Manufacturer Business 4/13/21
https://www.pharmexec.com/view/covid-s-tactical-impact-on-health-plan-manufacturer-business
Continuity and Decline of the Pharma Value Proposition 10/29/20
https://www.pharmexec.com/view/continuity-and-decline-of-the-pharma-value-proposition
Boomerang Effect Of Gene Therapy on Oncology Contracting 2/11/19
https://www.pharmacytimes.com/view/boomerang-effect-of-gene-therapy-on-oncology-contracting
Oncology Economics 5/15/18
